The share price would have dropped regardless, whether due to a company announcement that TGA had requested more data, or ultimately, as happened, the company withdrew the application, followed by a FOI making the report public. This situation has nothing to do with the Financial Review accusation of insider trading.
To his credit, OB has significantly upped his involvement since the departure of the former CEO, whom I believe he relied too heavily upon, and possibly also believed his overly optimistic reports.
I'm OB wants to commercialise Colostat for all stakeholders benefit including his own. It's hardly worth the work, stress and money for someone who is already very wealthy otherwise.
RHY Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
